Press Release

Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ® Read more
lab testing

Advancing Vaccines
For Better Lives

Welcome to Valneva

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Our focused pipeline includes the world’s first vaccine against the chikungunya virus, the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.

Learn More

Check out our 2022 Annual Business Report

Learn More

Follow Us

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

🎉🏆Congratulations are in order for our Valneva Scotland colleagues, who picked up the Innovation & Resilience award at Friday’s West Lothian Chamber of Commerce Business Excellence Ceremony! #LifeAtValneva #Innovation #Resilience


Load More